Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies
about
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint InflammationEditors' pick 2013.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.Therapeutic Benefits of Spleen Tyrosine Kinase Inhibitor Administration on Binge Drinking-Induced Alcoholic Liver Injury, Steatosis, and Inflammation in MicePharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.Advances in the use of prodrugs for drug delivery to the eye.Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies.Fostamatinib for persistent/chronic adult immune thrombocytopenia.
P2860
Q28552367-BDEB977F-8246-49E2-995F-18D07716724DQ33582058-4C6A37E3-0C0D-4F40-99F5-0E12349EDBDEQ36533710-EC106F14-E7DE-4427-A2B8-270A22B21AE8Q37059252-CECC98E0-5B2C-4B39-89E3-11FD0BD5D1C5Q38544216-8C2C6A06-8E3E-4757-8D75-5F1A3A8F5ABFQ38840351-D5472B1D-A162-4232-A1FC-1B62BB52A7FAQ38904119-59A91A5F-1F9D-4C60-90E2-13DD155B7673Q39682952-3FABE091-87E5-49FC-AE46-70D29A5DA4E3Q40699579-33EDCB6B-21F8-46C9-B783-70D2F7C0D52BQ41773428-18976B52-887B-4B50-8ABE-68054A92B3E5Q50282432-D00C549A-AE31-4495-AF0B-B31044D2AA77Q51321228-B4A98ABB-323E-4646-A919-5D67AA388F0DQ54144290-A9C33D43-B32D-4CC1-9D70-9DB2707CA6F0
P2860
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacokinetics of fostamatin ...... osing in three phase I studies
@en
type
label
Pharmacokinetics of fostamatin ...... osing in three phase I studies
@en
prefLabel
Pharmacokinetics of fostamatin ...... osing in three phase I studies
@en
P2093
P2860
P356
P1476
Pharmacokinetics of fostamatin ...... osing in three phase I studies
@en
P2093
David T W Lau
Elliott B Grossbard
Muhammad Baluom
P2860
P356
10.1111/BCP.12048
P407
P577
2013-07-01T00:00:00Z